Prev Close | 89.45 |
Open | 90.55 |
Day Low/High | 88.60 / 90.78 |
52 Wk Low/High | 36.75 / 99.23 |
Volume | 35.19M |
Prev Close | 89.45 |
Open | 90.55 |
Day Low/High | 88.60 / 90.78 |
52 Wk Low/High | 36.75 / 99.23 |
Volume | 35.19M |
Exchange | NASDAQ |
Shares Outstanding | 1202.71B |
Market Cap | 107.58B |
P/E Ratio | 120.88 |
Div & Yield | N.A. (N.A) |
A small trading position or bull call spread might be warranted, depending on support.
Perhaps not as a long-term investment, but the giant chipmaker could make for a good short-term trade.
Plus, it may be early to call it a worry, but keep a good eye out for inflation.
Not much is expected when CSCO reports fiscal Q4 earnings. Here's how I'm playing it.
While many tech companies topped their Q2 sales and earnings estimates, some made it clear that they're not out of the woods yet.
It is going to take successful vaccines and therapies and much lower unemployment to revive most of Walt Disney Co.'s businesses.
While valuations are clearly very high for many tech names, investor euphoria might not go away until news flow meaningfully worsens.
Blame the Fed? No. I'm reserving my wrath for the clueless buyers who appear to have taken a permanent intellectual summer vacation.
Plus, Russia could provide a real-time clinical trial of a coronavirus vaccine.
The GPU giant could see value in ARM's large mobile footprint and budding server CPU efforts. But a deal would also present some challenges.
Let me disabuse you of some of the biggest canards that people routinely spout involving the Fed and stocks.
I like owning these calls out to September.
Selling is broadening and speculative trading is narrowing, but it's tough to read too much into either yet.
Precious metals reverse on a strong dollar, which should trigger some rotational action.
Negotiations on the next round of stimulus, more so than tension between Washington and Beijing, and more so than earnings season, will control short-term financial market performance.
Let's review the charts and indicators.
What has changed significantly has been the value of the U.S. dollar relative to peer currencies.
FATMAANN names are leading to the downside, but small-caps and value are outperforming.
Plus, why shares of vaccine maker Moderna are taking a hit.
The delayed arrival of CPUs relying on Intel's 7nm manufacturing process node stands to make things easier for AMD in 2022 -- and perhaps longer.
Earnings reports continue to outperform, but can this support equity markets at these levels now?
Big Blue reported strong mainframe and Red Hat growth for Q2. But various other businesses had a rougher time.
Let's review the charts and indicators once again.
Amazon's public cloud is still unmatched in terms of the number of services and apps it supports, and is also still launching and updating offerings at an unmatched pace.
MU's cloud integration and migration to the cloud remains a main business theme driving capital expenditure on the data center.
I wouldn't get out of NVDA. No way. I would consider taking some profit off of the table up here.
Macro pressures, new AMD CPU launches and Apple's plans to ship its first Macs containing its own processors are all potential headwinds.
Honor your stops, keep cash levels higher, and likely be more aggressive with the names you trade.
AWS, Google Search and Nvidia each show how a market leader's unmatched R&D budget can make it tough to dislodge.
With more ways to differentiate processors, chip markets are fragmenting and R&D activity is growing.